SlideShare ist ein Scribd-Unternehmen logo
1 von 78
Downloaden Sie, um offline zu lesen
ANTIHAEMOSTATICS
ASSIGNMENT PRESENTED TO
DR SUJITH S
ASST PROFESSOR , DEPT OF VPT ,
COVAS , POOKODE
PRESENTED BY
DR SINDHU K
MVSc SCHOLAR
AGENTS WHICH REDUCES HEMOSTASIS /
BLOOD CLOTTING
1) ANTICOAGULANTS
In vitro & systemic
2) THROMBOLYTICS
Plasminogen activators
3) ANTIPLATELET DRUGS
COX inhibitors , glycoprotein IIa/IIIb inhibitors ,
thromboxane inhibitors & ADP inhibitors
Components of hemostatic System:-
1) Platelets
2) Plasma proteins – Coagulation & Fibrinolytic factors &
inhibitors
3) Vessel wall itself(endothelium)
Steps of normal homeostasis :-
1} platelet plug formation
• Adhesion, activation, aggregation
2}Fibrin clot formation
• Coagulation - intrinsic
- extrinsic
3}Dissociation of clot
Vascular Injury
Exposure of collagen and vWF Tissue factor exposure
Platelet adhesion and release Activation of coagulation
Platelet recruitment and
activation
Thrombin generation
Fibrin formationPlatelet aggregation
Platelet – fibrin thrombus
ANTI COAGULANTS
1] In vitro use
To prevent clotting of blood for transfusion or
diagnostic use
2] In vivo use
To prevent development & enlargement of thrombi
IN-VITRO ANTICOAGULANTS
• For lab purposes – sodium oxalates , sodium fluoride ,
EDTA
• For blood transfusion – ACD solution , CPDA-1 solution
OXALATES
1} sodium oxalate – combines with blood calcium forming
insoluble calcium oxalate rendering calcium unavailable for
blood coagulation
Dose – conc of 20 % @ level of blood
0.01 ml / 1 ml blood ( 2mg/ml)
ALL OXALATE SALTS ARE TOXIC
Contraindicated – blood transfusion
-- systemic use
SODIUM FLUORIDE
• Excellent anticoagulant for blood glucose studies bcoz it
interferes with enzymes involved in glycolysis
• It acts as preservative
• Dose 2.5 mg / ml of blood for blood glucose preservation
ETHYLENE DIAMINE TETRA ACETIC ACID
• EDTA ( edetate disodium , USP )
MOA – Na & K salts of EDTA chelates blood calcium thus preventing
clotting
• Lab application
1} hematological count { thrombocyte count }
bcoz Cellular details preserved
Dose – 1 mg / 5 ml of blood
0.01 ml of 2 % EDTA solution / ml of blood
BLOOD TRANSFUSION
1] Acid Citrate Dextrose , USP
Sodium citrate – 25 g
Citric acid – 8 g
Dextrose – 24.5 g
Distilled water to make volume of 1000 ml
Dose – at level of 15 ml / 100 ml of blood
Toxicity in dogs should not cross 286mg/kg
`
2] Citric Phosphate Dextrose Adenine CPDA-1
In DOGS maintains high levels of erythrocyte post transfusion
viability up to 20 days
3] Heparin
In cats - To collect small quantity of blood ( 50 ml )for
transfusion
Lab purpose : 8 – 10 units of heparin / ml of blood
Blood transfusion : 4 – 6 units of heparin / ml of blood
SYSTEMIC ANTICOAGULANTS
1} Heparin & related compounds
2} Inhibitors of vitamin K
3} Direct inhibitors of coagulation factors
4} Miscellaneous anticoagulants
HEPARIN ( HEPARIN SODIUM , USP )
• Pharmaceutical graded heparin is prepared from bovine lung tissue
or porcine intestinal mucosa
• It is a heterogenous mixture of anionic sulfated mucopolysaccharide
with molecular weight ranging from 1200 – 40000 daltons.
• Sodium salts used in vivo.
• Calcium salts , potassium salts – therapeutic use.
MOA
• Anti coagulatory effect of heparin – the reversible binding of
heparin to AT III , a protease inhibitor & Heparin Co factor II
• Binded heparin accelerates the velocity of interaction between
coagulant inhibitory factors & clotting factors
• LMWH – inactivates only factor Xa
• HMWH – inactivates thrombin & blocks conversion of fibrinogen
to fibrin , neutralizes activated factor IX
ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE
P K & P D
• Administered dose of heparin bounds extensively: endothelial cells
macrophages
plasma
proteins
Stored pools ~> saturated ~> free heparins ~>plasma ~> excretion
kidney
Metabolism – liver
- Reticulo endothelial system
CLINICAL INDICATION
• Prevention / treatment of venous thrombosis ( red thrombus )
• Pulmonary embolism
• Management of DIC
• Arterial fibrillation with embolization
Eg: feline cardiomyopathy
• Other potential coagulable states
Eg: cushing`s disease
nephrotic syndrome
cardiomyopathy
GUIDE LINE FOR HEPARIN DOSAGE
1} High dose heparin therapy
Aims to increase APTT 1.5 – 2.5 times base line & ACT 1.2 – 1.4
times base line
Initial high loading dose is beneficial
Regular & frequent monitoring of clotting time s essential
Clinical indication – treatment of established THROMBOEMBOLI
Dogs : 150 – 250 U / kg TID
Cats : 250 – 375 U / kg TID
2} LOW DOSE HEPARIN THERAPY
Dogs : treatment & management of Heart worm infestation
Initial dose 100 – 200 U / kg i/v followed by 50 U / kg every 3 hours
Maintenance dose 40 – 80 U / kg TID s/c
Cats : treatment of feline cardiomyopathy
200 U / kg s/c TID
Horses : management of DIC
high grade DIC : 80 – 100 U / kg i/v after 4-5 hr repetation
low grade DIC : 25 – 40 U / kg s/c BID / TID daily
MANAGEMENT OF DIC ~ DISSEMINATED
INTRAVASCULAR COAGULOPATHY
Heparin + blood / plasma
Low dose regimen for management
Small animals : 75 U / kg TID
Horses : 25 – 100 U / kg TID
Effect on APTT = minimum
LOW MOLECULAR WEIGHT HEPARINS
• Are short chain of polysaccharide with molecular weight of 1000-
10000 Da
• Isolated from standard heparin by techniques
- Gel filtration chromatography
- differential precipitations with ethanol
Advantages: better absorption from s/c injection
: prolonged elimination half life
: lower incidences of hemorrhagic complications
MOA
• LMWH selectively inhibit factor Xa with little effect on thrombin ,
Factor II ~> result is little effect on APTT & whole blood clotting
time
• LMWH less anti platelet action
• Commercial preparations – Ardeparin , Bemiparin , Dalteparin ,
Enoxaparin , Reviparin ,
Nadroparin ,
Tinzaparin
ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE
HEPARINOIDS
• Non heparin naturally occurring & synthetic sulphated
glycosaminoglycans which posses heparin like anticoagulant
action
1} DANAPAROID (Orgaron*)
Mixture of non heparin glycosamines isolated from porcine
intestinal mucosa
Orgaron* consists ~ heparin sulphate 80 %
~ dermatan sulphate 8 -16 %
~ chondroitin sulphate < 8.5 %
MOA
• Acts mainly by enhancing the inhibition of factor Xa by
antithrombine
• Danaproid exerts a strong catalytic effects on the inactivation of
factor Xa than on the inactivation of thrombin
Clinical indications
• Prevention of DEEP VEIN THROMBOSIS ( DVT ) following
orthopaedic , major abdominal & thoracic surgery
• Patients with positive diagnosis of non hemorrhagic stroke
OTHER DRUGS
1] drotrecogin alfa
2] dextran sulphate
3] sulodexide
VITAMIN K ANTAGONISTS
• Inhibitors of vitamin K often called as ORAL
ANTICOAGULANTS
• VIT K antagonists are active ORALLY (only IN VIVO )
• Studies in veterinary medicine focused primarily on their TOXIC
effects rather than on therapeutic indications
TYPES
1} Coumarin derivatives
2} Indanedione derivatives
COUMARIN DERIVATIVES
• Coumadins are synthetic oral anticoagulants derived from the
molecule 4 hydroxycoumarin
1} BISHYDROXYCOUMARIN – first oral AC synthesized by LINK
(1943-44)
Its a derivative of moldy / spoiled sweet clover which is responsible
for hemorrhagic disease in cattle in USA
2} WARFARIN SODIUM (USP)
2nd compound synthesized commercially
WARFARIN: MOA
• Inhibiton of hepatic synthesis of vit K dependent clotting
factor ~ Prothrombin
~ Factor VII , IX , X
~ anticoagulant protein C & S
Carboxylation results in the oxidative inactivation of vit K
Warfarin inhibits vit K epoxide reductase enzyme & interfere
with regeneration of active form of vit K thereby inhibiting
synthesis of prothrombin & factor VII , IX , X
ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE
`
• Warfarin acts as AC only IN VIVO bcoz they act indirectly by
interfering with synthesis of clotting factors
• AC effects develops over several hours but peak plasma level
occurs in 1 hour after oral administration onset takes 6 -12 hours
with full benefits realized after (2-3 days) & long duration of
action (4-7 days)
• bcoz of persistence of factors synthesized before drug
administration & of long half life
• Rapidly & completely absorbed from intestine
• Metabolised in liver ~ inactive metabolites cytochrome P450
system
ADVERSE EFFECTS
• Acute internal bleeding/hemorrhage
• Clinical signs ~ anaemia , thrombocytopenia , hematuria etc
• Hemorrhages in brain & spinal column ~ ataxia , paresis ,
convulsions
• Periarticular hemorrhages ~ lamness , joint swelling , pain
LAB CONTROL
1} the quick test
2} the one stage prothrombin time
CLINICAL INDICATIONS
• Prophylaxis of venous thrombosis & Aortic/ pulmonary
thromboembolism
Horses : to relieve the clinical signs of NAVICULAR DISEASE
Dose @ 0.02 mg/kg PO once daily
Dogs : for prevention of recurrence of thrombotic conditions
Dose @ 0.1 – 0.2 mg/kg PO once daily
INDANEDIONE DERIVATIVES
• Are derivative of indane-1,3-dione
• Structurally related to coumarins & produce anticoagulation
activity by mechanism involving ANTAGONISM OF VITAMIN
K
• Reports to cause kidney damage, sensitivity reactions,
leucopenia in humans. Hence retricted drugs category
• Use in vety practice not reported yet
Eg: Anisindione , phenindione , clorindione , diphenadione
DIRECT INHIBITORS OF COAGULATION
FACTORS
1} Direct inhibitors of factor Xa – Xabans
-- Rivaroxabans
2} Direct inhibitors of coagulation factor II – hirudin
-- bivalirudin
-- desirudin &
lepirdin
3} Direct thrombin inhibitors – argatroban
-- dabigatran
END OF TOPIC - ANTICOAGULANTS
DISCUSSIONS
THROMBOLYTICS
• Drugs that enhances the conversion of the inactive
precursor plasminogen to the active fibrinolytic enzyme
plasmin
• 2 phases Plasminogen ~ plasma/soluble phase
• ~ gel phase
• Dissolves both physiologic as well as pathogenic thrombus =
TOXIC ,producing hemorrhage = major side effect
MOA
• When plasminogen activating agents + clot = activation of fibrin
bound gel phase plasminogen to plasmin locally with selective
fibrinolysis
• Instead soluble phase plasminogen circulating in systemic blood
also activated
• Adverse effect = increased tendency for systemic bleeding
• Plasmin formation occurs through out circulation =
overactivation of plasminogen , neutralizing endogenous
antagonist to plasmin a2 ANTIPLASMIN
THROMBOLYTIC DRUGS –
MECHANISM OF ACTION
THROMBOLYTIC DRUGS –
MECHANISM OF ACTION
THROMBOLYTIC DRUGS –
MECHANISM OF ACTION
THROMBOLYTIC DRUGS –
MECHANISM OF ACTION
FIRST GEN : STREPTOKINASE
• Streptokinase is a protein obtained from group C BETA
HEMOLYTIC STREPTOCOCCI
• Effective & inexpensive clot dissolving drug ~ MI
• ~ Pulmonary
embolism
• MOA :acts as plasminogen activator = enhances production of
plasmin by forming an active non covalent 1:1 complex
(streptokinase : plasminogen complex )
• Plasmin catalyzes degradation of plasma proteins = clotting factor
FIBRINOGEN & factor V , VII
ADVERSE EFFECT
• Foreign protein = Antigenic reactions
• 2nd time use = hypersensitivity & Anaphylaxis
• Over dosage = plasminogen depletion & SK resistance
• Treatment over-dosage FRESH PLASMA /AMINOCAPROIC
ACID
CLINICAL INDICATIONS
• Used locally as powder , infusion or irrigation of wounds which
don’t responds for antibacterial therapy – burns , ulcers , chronic
eczema , ear hematomas , otitis externa , osteomyelitis , chronic
sinusitis
• Parentrally ~ eczema , dermatitis , hematoma , trauma &
pneumonia
• Prophylaxis ~ reduction of post operative adhesions
• Dogs: 5000 – 10,000 U (total dose) IM IV in 2 divided doses 5 days
• Large animals : 5000 – 10,000 U / 45 kg BW , IM IV 2 divided
dose 5 – 6 days
SEC GEN : PLASMINOGEN ACTIVATORS
• Tissue plasminogen activators
• Alteplase
• Reteplase
• Urokinase
• Streptodornase
OTHER DRUGS ~ ancrod
~ fibrinolysin
ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE
MOA
• It catalyzes conversion of plasminogen to plasmin
• Selective action towards the plasminogen bound to fibrin & low
affinity for free plasminogen
• Thus fibrinolysis to the formed clot , with out unwanted degradation
of other proteins
Clinical indication
1} thromboembolic strokes
2} deep vein thrombosis
3} pulmonary embolism to clear a blocked artery
ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE
• ALTEPLASE – treatment of aortic thromboembolism
Cats : 0.25 – 1 mg/kg/hour , i/v infusion for total dose of 1-10
mg/kg
Dogs : 0.01 microgram/kg/min , i/v infusion for 30 min
• UROKINASE – to prevent post operative lesions
Dogs : 5000 – 10,000 units/kg , intra-peritoneal lavage
END OF TOPIC - THROMBOLYTICS
DISCUSSIONS
ANTITHROMBOTIC DRUGS
ANTITHROMBOTIC DRUGS
ANTITHROMBOTIC DRUGS
ANTITHROMBOTIC DRUGS
THE ROLE OF PLATELETS
THE ROLE OF PLATELETS
THE ROLE OF PLATELETS
THE ROLE OF PLATELETS
ANTITHROMBOTIC DRUGS
Antiplatelet drugs
Acetylsalicylic
acid (aspirin)
P2Y12
antagonists
Dipyridamole GPIIb/IIIa
antagonists
Used widely
in patients
at risk of
thromboembolic
disease
Beneficial in the
treatment and
prevention of ACS
and the prevention
of thromboembolic
events
Secondary
prevention in
patients following
stroke, often in
combination with
aspirin
Administered
intravenously, are
effective during
percutaneous
coronary
intervention (PCI)
COX INHIBITORS
• Aspirin ~ NSAID
• MOA = irreversibly inactivates cyclooxygenase enzyme to produce
pharmacological effects
Reduces synthesis of thromboxane A2 = potent vasoconstrictor &
inducer of platelet aggregation
• Irreversibly acetylate thromboxane synthase , enzyme responsible
for thromboxane synthesis
• Low dose = effective in reducing platelet aggregation
• High dose = blocks synthesis of prostacyclin reducing over all anti
aggregatory effect
Plaque Disruption
Collagen vWF
Platelet adhesion and secretion
Aspirin
Thrombin generation
Abciximab
Eptifibatide
Tirofiban
Platelet aggregation
Platelet recruitment and activation
X COX-1
TXA2
ADP
X
GPllb / llla activation
X
CYCLOOXYGENASE INHIBITORS –
MECHANISM OF ACTION
ACETYLSALICYLIC ACID –
MECHANISM OF ACTION
ACETYLSALICYLIC ACID –
MECHANISM OF ACTION
ACETYLSALICYLIC ACID –
MECHANISM OF ACTION
ACETYLSALICYLIC ACID –
MECHANISM OF ACTION
GLYCOPROTEIN II B / III A INHIBITORS
• NEW CLASES of potent platelet aggregation agonists
• MOA – acts by blocking glycoprotein II b / III a receptors present on
surface of platelets
• Glycoprotein II b / III a complex functions as receptor = vWB factor
through which agonists collagen , thrombin , thromboxanes , ADP
induces platelet aggregation
• Drugs:
1} Abciximax – treatment of ANGIOPLASTY
2} EPTIFIBTIDE
2} tirofiban
GPIIB/IIIA-RECEPTOR ANTAGONISTS –
MECHANISM OF ACTION
GPIIB/IIIA-RECEPTOR ANTAGONISTS –
MECHANISM OF ACTION
GPIIB/IIIA-RECEPTOR ANTAGONISTS –
MECHANISM OF ACTION
GPIIB/IIIA-RECEPTOR ANTAGONISTS –
MECHANISM OF ACTION
GPIIB/IIIA-RECEPTOR ANTAGONISTS –
MECHANISM OF ACTION
THROMBOXANE INHIBITORS
• Acts through inhibition of thromboxane synthetase = decreases
synthesis of TXA2 thus prevents platelet aggregation
• Elevates endogenous cAMP in the platelets by inhibiting
phosphodiesterase enzyme
• Blockade of cellular reuptake of adenosine into platelets ,RBC &
endothelial cells =increased extra cellular concentration of
adenosine
,
1} DIPYRIDAMOLE
As synergistic with ASPIRIN
With WARFARIN – to decrease the incidence of thromboembolisim in
patients with PROSTHETIC HEART VALVES
2}DAZOXIBEN
3}PICOTAMIDE
4}TERUTROBAN
MISCELLANEOUS DRUGS
• CILOSTAZOL : phosphodiesterase inhibitor = intracellular
concentration of cAMP = increase in PK-A = inhibition of platelet
aggregation & arterial vasodilator effect
Treatment – muscular pains due to cramps , numbness or fatigue
• TIMOLOL ( b adrenoceptor blocker )
synergizes action of low dose aspirin
• SULFINPYRAZONE uricosuric drug related to phenylbutazone
Inhibits COX enzyme = blocks production of prostanoids
REFERENCES
• H RICHARD ADAMS Veterinary pharmacology and therapeutics, 8th edition.
• GOODMAN & GILMAN`S The pharmacological basis of therapeutics, 11th edition.
• HS SANDHU Essentials of veterinary pharmacology and toxicology, 2nd edition.
• GOOGLE IMAGES
• ONLINE SEARCH RELATED TOPICS
THANK YOU

Weitere ähnliche Inhalte

Was ist angesagt?

Canine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPI
Canine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPICanine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPI
Canine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPIDr. Jibachha Sah
 
Etiopathogenesis, therapy, prevention and control of milk fever in dairy cattle
Etiopathogenesis, therapy, prevention and control of milk fever in dairy cattleEtiopathogenesis, therapy, prevention and control of milk fever in dairy cattle
Etiopathogenesis, therapy, prevention and control of milk fever in dairy cattleRadhika Vaidya
 
Post parturient-hemoglobinuria
Post parturient-hemoglobinuriaPost parturient-hemoglobinuria
Post parturient-hemoglobinuriaJalal Syooti
 
Equine trypanosomiasis(dourine)
Equine trypanosomiasis(dourine)Equine trypanosomiasis(dourine)
Equine trypanosomiasis(dourine)fraol birhanu
 
Strangles handout
Strangles handoutStrangles handout
Strangles handoutAmandine Ta
 
Ear new affection of ear and its treatment
Ear new affection of ear and its treatmentEar new affection of ear and its treatment
Ear new affection of ear and its treatmentBikas Puri
 
Epidural Anesthesia in Bovine
Epidural Anesthesia  in BovineEpidural Anesthesia  in Bovine
Epidural Anesthesia in BovineDR AMEER HAMZA
 
Local anesthesia and nerve blocks in large animals.
Local anesthesia and nerve blocks in large animals.Local anesthesia and nerve blocks in large animals.
Local anesthesia and nerve blocks in large animals.GangaYadav4
 
Infectious bovine rhinotracheitis
Infectious bovine rhinotracheitisInfectious bovine rhinotracheitis
Infectious bovine rhinotracheitisAlex Vet
 

Was ist angesagt? (20)

HEMOSTATIC DRUGS IN SMALL ANIMAL PRACTICE
HEMOSTATIC DRUGS IN SMALL ANIMAL PRACTICEHEMOSTATIC DRUGS IN SMALL ANIMAL PRACTICE
HEMOSTATIC DRUGS IN SMALL ANIMAL PRACTICE
 
Ulcerative lymphangitis
Ulcerative lymphangitisUlcerative lymphangitis
Ulcerative lymphangitis
 
Canine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPI
Canine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPICanine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPI
Canine babesiosis Dr.Jibachha Sah,M.V.Sc ,Lecturer NPI
 
Etiopathogenesis, therapy, prevention and control of milk fever in dairy cattle
Etiopathogenesis, therapy, prevention and control of milk fever in dairy cattleEtiopathogenesis, therapy, prevention and control of milk fever in dairy cattle
Etiopathogenesis, therapy, prevention and control of milk fever in dairy cattle
 
Canine ehrlichiosis
Canine ehrlichiosisCanine ehrlichiosis
Canine ehrlichiosis
 
Fluid therapy in animals
Fluid therapy in animalsFluid therapy in animals
Fluid therapy in animals
 
Post parturient-hemoglobinuria
Post parturient-hemoglobinuriaPost parturient-hemoglobinuria
Post parturient-hemoglobinuria
 
ANTI-ANEMIC DRUGS IN VETERINARY PRACTICE
ANTI-ANEMIC DRUGS IN VETERINARY PRACTICE ANTI-ANEMIC DRUGS IN VETERINARY PRACTICE
ANTI-ANEMIC DRUGS IN VETERINARY PRACTICE
 
Hypomagnesaemia
HypomagnesaemiaHypomagnesaemia
Hypomagnesaemia
 
Equine trypanosomiasis(dourine)
Equine trypanosomiasis(dourine)Equine trypanosomiasis(dourine)
Equine trypanosomiasis(dourine)
 
AN OVERVIEW OF BUFFALOE MAMMILITIS AND THERAPY
AN OVERVIEW OF  BUFFALOE MAMMILITIS AND THERAPY AN OVERVIEW OF  BUFFALOE MAMMILITIS AND THERAPY
AN OVERVIEW OF BUFFALOE MAMMILITIS AND THERAPY
 
UTERINE TORSION
UTERINE TORSIONUTERINE TORSION
UTERINE TORSION
 
Vagus indigestion
Vagus indigestionVagus indigestion
Vagus indigestion
 
Strangles handout
Strangles handoutStrangles handout
Strangles handout
 
Deg nala disease
Deg nala diseaseDeg nala disease
Deg nala disease
 
Ear new affection of ear and its treatment
Ear new affection of ear and its treatmentEar new affection of ear and its treatment
Ear new affection of ear and its treatment
 
Epidural Anesthesia in Bovine
Epidural Anesthesia  in BovineEpidural Anesthesia  in Bovine
Epidural Anesthesia in Bovine
 
Bovine ketosis
Bovine ketosisBovine ketosis
Bovine ketosis
 
Local anesthesia and nerve blocks in large animals.
Local anesthesia and nerve blocks in large animals.Local anesthesia and nerve blocks in large animals.
Local anesthesia and nerve blocks in large animals.
 
Infectious bovine rhinotracheitis
Infectious bovine rhinotracheitisInfectious bovine rhinotracheitis
Infectious bovine rhinotracheitis
 

Andere mochten auch

Use Of Tissue Sealants And Hemostatic Agents
Use Of Tissue Sealants And Hemostatic AgentsUse Of Tissue Sealants And Hemostatic Agents
Use Of Tissue Sealants And Hemostatic AgentsMCG Urology
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang HospitalRashidi Ahmad
 
Topical hemostatic agents in surgical practice
Topical hemostatic agents in surgical practiceTopical hemostatic agents in surgical practice
Topical hemostatic agents in surgical practiceanemo_site
 
Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo Antonio Raviele
 
Antiplatelets, & fibrinolytics
Antiplatelets, & fibrinolytics Antiplatelets, & fibrinolytics
Antiplatelets, & fibrinolytics Harshit Sheth
 
Drug interactions of Low Molecular weight Heparins (LMWHs)
Drug interactions of Low Molecular weight Heparins (LMWHs)Drug interactions of Low Molecular weight Heparins (LMWHs)
Drug interactions of Low Molecular weight Heparins (LMWHs)Naina Mohamed, PhD
 
Dr. adil routes of drugs
Dr. adil routes of drugsDr. adil routes of drugs
Dr. adil routes of drugsdraadil
 
Fibrinolytics & antifibrinolytics
Fibrinolytics & antifibrinolyticsFibrinolytics & antifibrinolytics
Fibrinolytics & antifibrinolyticsElza Emmannual
 

Andere mochten auch (20)

Veterinary product
Veterinary product Veterinary product
Veterinary product
 
Use Of Tissue Sealants And Hemostatic Agents
Use Of Tissue Sealants And Hemostatic AgentsUse Of Tissue Sealants And Hemostatic Agents
Use Of Tissue Sealants And Hemostatic Agents
 
Mtica
MticaMtica
Mtica
 
CARDIOVASCULAR SYSTEM
CARDIOVASCULAR SYSTEMCARDIOVASCULAR SYSTEM
CARDIOVASCULAR SYSTEM
 
CONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGY
CONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGYCONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGY
CONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGY
 
Drugs acting on CNS (veterinary)
Drugs acting on CNS (veterinary)Drugs acting on CNS (veterinary)
Drugs acting on CNS (veterinary)
 
CONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGY
CONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGYCONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGY
CONTRIBUTION OF SCIENTISTS IN THE FIELD OF VETERINARY PHARMACOLOGY
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang Hospital
 
26.fibrinolytics
26.fibrinolytics26.fibrinolytics
26.fibrinolytics
 
Expt. ani. models
Expt. ani. modelsExpt. ani. models
Expt. ani. models
 
Drugs affecting thrombosis
Drugs affecting thrombosisDrugs affecting thrombosis
Drugs affecting thrombosis
 
Reinfarction after thrombolytics
Reinfarction after thrombolyticsReinfarction after thrombolytics
Reinfarction after thrombolytics
 
Topical hemostatic agents in surgical practice
Topical hemostatic agents in surgical practiceTopical hemostatic agents in surgical practice
Topical hemostatic agents in surgical practice
 
Introduction to fluid & electrolyte balance in animals
Introduction to fluid & electrolyte balance in animalsIntroduction to fluid & electrolyte balance in animals
Introduction to fluid & electrolyte balance in animals
 
Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo
 
Antiplatelets, & fibrinolytics
Antiplatelets, & fibrinolytics Antiplatelets, & fibrinolytics
Antiplatelets, & fibrinolytics
 
Drug interactions of Low Molecular weight Heparins (LMWHs)
Drug interactions of Low Molecular weight Heparins (LMWHs)Drug interactions of Low Molecular weight Heparins (LMWHs)
Drug interactions of Low Molecular weight Heparins (LMWHs)
 
Dr. adil routes of drugs
Dr. adil routes of drugsDr. adil routes of drugs
Dr. adil routes of drugs
 
Clinical pathophysiology f toxic plants
Clinical pathophysiology f toxic plantsClinical pathophysiology f toxic plants
Clinical pathophysiology f toxic plants
 
Fibrinolytics & antifibrinolytics
Fibrinolytics & antifibrinolyticsFibrinolytics & antifibrinolytics
Fibrinolytics & antifibrinolytics
 

Ähnlich wie ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE

Ähnlich wie ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE (20)

Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Seminar drug used in paediatric cardiology
Seminar drug used in paediatric cardiologySeminar drug used in paediatric cardiology
Seminar drug used in paediatric cardiology
 
Anticoagulants Nursing esther
Anticoagulants Nursing estherAnticoagulants Nursing esther
Anticoagulants Nursing esther
 
6-rodenticides.pptx
6-rodenticides.pptx6-rodenticides.pptx
6-rodenticides.pptx
 
anticoagulants
anticoagulantsanticoagulants
anticoagulants
 
Drugs affecting coagulation and anticoagulants
Drugs affecting coagulation and anticoagulantsDrugs affecting coagulation and anticoagulants
Drugs affecting coagulation and anticoagulants
 
Anticoagulants by gyanendra kp
Anticoagulants by gyanendra kpAnticoagulants by gyanendra kp
Anticoagulants by gyanendra kp
 
anticoagulants.pptx
anticoagulants.pptxanticoagulants.pptx
anticoagulants.pptx
 
Coagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptxCoagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptx
 
ANTICOAGULANTS
ANTICOAGULANTSANTICOAGULANTS
ANTICOAGULANTS
 
Pharmacology of Anticoagulants, antiplatelets
 Pharmacology of Anticoagulants, antiplatelets Pharmacology of Anticoagulants, antiplatelets
Pharmacology of Anticoagulants, antiplatelets
 
Drugs coagulation lecture
Drugs coagulation lectureDrugs coagulation lecture
Drugs coagulation lecture
 
Antixcoagulants
AntixcoagulantsAntixcoagulants
Antixcoagulants
 
Drugs influencing coagulation .pptx
Drugs influencing coagulation .pptxDrugs influencing coagulation .pptx
Drugs influencing coagulation .pptx
 
ANTICOAGULANTS.pptx
ANTICOAGULANTS.pptxANTICOAGULANTS.pptx
ANTICOAGULANTS.pptx
 
Anticoagulants medications
Anticoagulants medications Anticoagulants medications
Anticoagulants medications
 
Anticoagulants.pptx
Anticoagulants.pptxAnticoagulants.pptx
Anticoagulants.pptx
 
HYPERTENSION - PHARMACOTHERAPY
HYPERTENSION - PHARMACOTHERAPYHYPERTENSION - PHARMACOTHERAPY
HYPERTENSION - PHARMACOTHERAPY
 
Acute renal disease
Acute renal diseaseAcute renal disease
Acute renal disease
 
coagulantandanticoagulant-170905090544.pdf
coagulantandanticoagulant-170905090544.pdfcoagulantandanticoagulant-170905090544.pdf
coagulantandanticoagulant-170905090544.pdf
 

Mehr von Dr. Sindhu K., Asst. Prof., Dept. of VPT, VCG. (12)

Bioassay techniques
Bioassay techniquesBioassay techniques
Bioassay techniques
 
IPR history
IPR historyIPR history
IPR history
 
Phytochemical screening
Phytochemical screeningPhytochemical screening
Phytochemical screening
 
PHYTOCHEMICAL EXTRACTION
PHYTOCHEMICAL EXTRACTIONPHYTOCHEMICAL EXTRACTION
PHYTOCHEMICAL EXTRACTION
 
Chemical constituents of poisonous plants
Chemical constituents of poisonous plantsChemical constituents of poisonous plants
Chemical constituents of poisonous plants
 
Introduction to Veterinary General toxicology
Introduction to Veterinary General toxicologyIntroduction to Veterinary General toxicology
Introduction to Veterinary General toxicology
 
Adrenergic agonists & antagonists in veterinary medicine
Adrenergic agonists & antagonists in veterinary medicine Adrenergic agonists & antagonists in veterinary medicine
Adrenergic agonists & antagonists in veterinary medicine
 
Catecholamines & noncatecholamines
Catecholamines & noncatecholaminesCatecholamines & noncatecholamines
Catecholamines & noncatecholamines
 
Neuro humoral transmission
Neuro humoral transmissionNeuro humoral transmission
Neuro humoral transmission
 
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIESACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
 
ANTIARRHYTHMIC AGENTS IN VETERINARY PRACTICE.
ANTIARRHYTHMIC AGENTS IN VETERINARY PRACTICE.ANTIARRHYTHMIC AGENTS IN VETERINARY PRACTICE.
ANTIARRHYTHMIC AGENTS IN VETERINARY PRACTICE.
 
Animal models in toxicological studies
Animal models in toxicological studiesAnimal models in toxicological studies
Animal models in toxicological studies
 

Kürzlich hochgeladen

2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICESayali Powar
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphNetziValdelomar1
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 

Kürzlich hochgeladen (20)

Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICE
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
Prelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quizPrelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quiz
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a Paragraph
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 

ANTI-HEMOSTATIC DRUGS IN VETERINARY PRACTICE

  • 1. ANTIHAEMOSTATICS ASSIGNMENT PRESENTED TO DR SUJITH S ASST PROFESSOR , DEPT OF VPT , COVAS , POOKODE PRESENTED BY DR SINDHU K MVSc SCHOLAR
  • 2. AGENTS WHICH REDUCES HEMOSTASIS / BLOOD CLOTTING 1) ANTICOAGULANTS In vitro & systemic 2) THROMBOLYTICS Plasminogen activators 3) ANTIPLATELET DRUGS COX inhibitors , glycoprotein IIa/IIIb inhibitors , thromboxane inhibitors & ADP inhibitors
  • 3. Components of hemostatic System:- 1) Platelets 2) Plasma proteins – Coagulation & Fibrinolytic factors & inhibitors 3) Vessel wall itself(endothelium) Steps of normal homeostasis :- 1} platelet plug formation • Adhesion, activation, aggregation 2}Fibrin clot formation • Coagulation - intrinsic - extrinsic 3}Dissociation of clot
  • 4. Vascular Injury Exposure of collagen and vWF Tissue factor exposure Platelet adhesion and release Activation of coagulation Platelet recruitment and activation Thrombin generation Fibrin formationPlatelet aggregation Platelet – fibrin thrombus
  • 5. ANTI COAGULANTS 1] In vitro use To prevent clotting of blood for transfusion or diagnostic use 2] In vivo use To prevent development & enlargement of thrombi
  • 6. IN-VITRO ANTICOAGULANTS • For lab purposes – sodium oxalates , sodium fluoride , EDTA • For blood transfusion – ACD solution , CPDA-1 solution
  • 7. OXALATES 1} sodium oxalate – combines with blood calcium forming insoluble calcium oxalate rendering calcium unavailable for blood coagulation Dose – conc of 20 % @ level of blood 0.01 ml / 1 ml blood ( 2mg/ml) ALL OXALATE SALTS ARE TOXIC Contraindicated – blood transfusion -- systemic use
  • 8. SODIUM FLUORIDE • Excellent anticoagulant for blood glucose studies bcoz it interferes with enzymes involved in glycolysis • It acts as preservative • Dose 2.5 mg / ml of blood for blood glucose preservation
  • 9. ETHYLENE DIAMINE TETRA ACETIC ACID • EDTA ( edetate disodium , USP ) MOA – Na & K salts of EDTA chelates blood calcium thus preventing clotting • Lab application 1} hematological count { thrombocyte count } bcoz Cellular details preserved Dose – 1 mg / 5 ml of blood 0.01 ml of 2 % EDTA solution / ml of blood
  • 10. BLOOD TRANSFUSION 1] Acid Citrate Dextrose , USP Sodium citrate – 25 g Citric acid – 8 g Dextrose – 24.5 g Distilled water to make volume of 1000 ml Dose – at level of 15 ml / 100 ml of blood Toxicity in dogs should not cross 286mg/kg
  • 11. ` 2] Citric Phosphate Dextrose Adenine CPDA-1 In DOGS maintains high levels of erythrocyte post transfusion viability up to 20 days 3] Heparin In cats - To collect small quantity of blood ( 50 ml )for transfusion Lab purpose : 8 – 10 units of heparin / ml of blood Blood transfusion : 4 – 6 units of heparin / ml of blood
  • 12. SYSTEMIC ANTICOAGULANTS 1} Heparin & related compounds 2} Inhibitors of vitamin K 3} Direct inhibitors of coagulation factors 4} Miscellaneous anticoagulants
  • 13. HEPARIN ( HEPARIN SODIUM , USP ) • Pharmaceutical graded heparin is prepared from bovine lung tissue or porcine intestinal mucosa • It is a heterogenous mixture of anionic sulfated mucopolysaccharide with molecular weight ranging from 1200 – 40000 daltons. • Sodium salts used in vivo. • Calcium salts , potassium salts – therapeutic use.
  • 14. MOA • Anti coagulatory effect of heparin – the reversible binding of heparin to AT III , a protease inhibitor & Heparin Co factor II • Binded heparin accelerates the velocity of interaction between coagulant inhibitory factors & clotting factors • LMWH – inactivates only factor Xa • HMWH – inactivates thrombin & blocks conversion of fibrinogen to fibrin , neutralizes activated factor IX
  • 16. P K & P D • Administered dose of heparin bounds extensively: endothelial cells macrophages plasma proteins Stored pools ~> saturated ~> free heparins ~>plasma ~> excretion kidney Metabolism – liver - Reticulo endothelial system
  • 17. CLINICAL INDICATION • Prevention / treatment of venous thrombosis ( red thrombus ) • Pulmonary embolism • Management of DIC • Arterial fibrillation with embolization Eg: feline cardiomyopathy • Other potential coagulable states Eg: cushing`s disease nephrotic syndrome cardiomyopathy
  • 18. GUIDE LINE FOR HEPARIN DOSAGE 1} High dose heparin therapy Aims to increase APTT 1.5 – 2.5 times base line & ACT 1.2 – 1.4 times base line Initial high loading dose is beneficial Regular & frequent monitoring of clotting time s essential Clinical indication – treatment of established THROMBOEMBOLI Dogs : 150 – 250 U / kg TID Cats : 250 – 375 U / kg TID
  • 19. 2} LOW DOSE HEPARIN THERAPY Dogs : treatment & management of Heart worm infestation Initial dose 100 – 200 U / kg i/v followed by 50 U / kg every 3 hours Maintenance dose 40 – 80 U / kg TID s/c Cats : treatment of feline cardiomyopathy 200 U / kg s/c TID Horses : management of DIC high grade DIC : 80 – 100 U / kg i/v after 4-5 hr repetation low grade DIC : 25 – 40 U / kg s/c BID / TID daily
  • 20. MANAGEMENT OF DIC ~ DISSEMINATED INTRAVASCULAR COAGULOPATHY Heparin + blood / plasma Low dose regimen for management Small animals : 75 U / kg TID Horses : 25 – 100 U / kg TID Effect on APTT = minimum
  • 21. LOW MOLECULAR WEIGHT HEPARINS • Are short chain of polysaccharide with molecular weight of 1000- 10000 Da • Isolated from standard heparin by techniques - Gel filtration chromatography - differential precipitations with ethanol Advantages: better absorption from s/c injection : prolonged elimination half life : lower incidences of hemorrhagic complications
  • 22. MOA • LMWH selectively inhibit factor Xa with little effect on thrombin , Factor II ~> result is little effect on APTT & whole blood clotting time • LMWH less anti platelet action • Commercial preparations – Ardeparin , Bemiparin , Dalteparin , Enoxaparin , Reviparin , Nadroparin , Tinzaparin
  • 24. HEPARINOIDS • Non heparin naturally occurring & synthetic sulphated glycosaminoglycans which posses heparin like anticoagulant action 1} DANAPAROID (Orgaron*) Mixture of non heparin glycosamines isolated from porcine intestinal mucosa Orgaron* consists ~ heparin sulphate 80 % ~ dermatan sulphate 8 -16 % ~ chondroitin sulphate < 8.5 %
  • 25. MOA • Acts mainly by enhancing the inhibition of factor Xa by antithrombine • Danaproid exerts a strong catalytic effects on the inactivation of factor Xa than on the inactivation of thrombin Clinical indications • Prevention of DEEP VEIN THROMBOSIS ( DVT ) following orthopaedic , major abdominal & thoracic surgery • Patients with positive diagnosis of non hemorrhagic stroke
  • 26. OTHER DRUGS 1] drotrecogin alfa 2] dextran sulphate 3] sulodexide
  • 27. VITAMIN K ANTAGONISTS • Inhibitors of vitamin K often called as ORAL ANTICOAGULANTS • VIT K antagonists are active ORALLY (only IN VIVO ) • Studies in veterinary medicine focused primarily on their TOXIC effects rather than on therapeutic indications TYPES 1} Coumarin derivatives 2} Indanedione derivatives
  • 28. COUMARIN DERIVATIVES • Coumadins are synthetic oral anticoagulants derived from the molecule 4 hydroxycoumarin 1} BISHYDROXYCOUMARIN – first oral AC synthesized by LINK (1943-44) Its a derivative of moldy / spoiled sweet clover which is responsible for hemorrhagic disease in cattle in USA 2} WARFARIN SODIUM (USP) 2nd compound synthesized commercially
  • 29. WARFARIN: MOA • Inhibiton of hepatic synthesis of vit K dependent clotting factor ~ Prothrombin ~ Factor VII , IX , X ~ anticoagulant protein C & S Carboxylation results in the oxidative inactivation of vit K Warfarin inhibits vit K epoxide reductase enzyme & interfere with regeneration of active form of vit K thereby inhibiting synthesis of prothrombin & factor VII , IX , X
  • 31. ` • Warfarin acts as AC only IN VIVO bcoz they act indirectly by interfering with synthesis of clotting factors • AC effects develops over several hours but peak plasma level occurs in 1 hour after oral administration onset takes 6 -12 hours with full benefits realized after (2-3 days) & long duration of action (4-7 days) • bcoz of persistence of factors synthesized before drug administration & of long half life • Rapidly & completely absorbed from intestine • Metabolised in liver ~ inactive metabolites cytochrome P450 system
  • 32. ADVERSE EFFECTS • Acute internal bleeding/hemorrhage • Clinical signs ~ anaemia , thrombocytopenia , hematuria etc • Hemorrhages in brain & spinal column ~ ataxia , paresis , convulsions • Periarticular hemorrhages ~ lamness , joint swelling , pain LAB CONTROL 1} the quick test 2} the one stage prothrombin time
  • 33. CLINICAL INDICATIONS • Prophylaxis of venous thrombosis & Aortic/ pulmonary thromboembolism Horses : to relieve the clinical signs of NAVICULAR DISEASE Dose @ 0.02 mg/kg PO once daily Dogs : for prevention of recurrence of thrombotic conditions Dose @ 0.1 – 0.2 mg/kg PO once daily
  • 34. INDANEDIONE DERIVATIVES • Are derivative of indane-1,3-dione • Structurally related to coumarins & produce anticoagulation activity by mechanism involving ANTAGONISM OF VITAMIN K • Reports to cause kidney damage, sensitivity reactions, leucopenia in humans. Hence retricted drugs category • Use in vety practice not reported yet Eg: Anisindione , phenindione , clorindione , diphenadione
  • 35. DIRECT INHIBITORS OF COAGULATION FACTORS 1} Direct inhibitors of factor Xa – Xabans -- Rivaroxabans 2} Direct inhibitors of coagulation factor II – hirudin -- bivalirudin -- desirudin & lepirdin 3} Direct thrombin inhibitors – argatroban -- dabigatran
  • 36. END OF TOPIC - ANTICOAGULANTS DISCUSSIONS
  • 37. THROMBOLYTICS • Drugs that enhances the conversion of the inactive precursor plasminogen to the active fibrinolytic enzyme plasmin • 2 phases Plasminogen ~ plasma/soluble phase • ~ gel phase • Dissolves both physiologic as well as pathogenic thrombus = TOXIC ,producing hemorrhage = major side effect
  • 38. MOA • When plasminogen activating agents + clot = activation of fibrin bound gel phase plasminogen to plasmin locally with selective fibrinolysis • Instead soluble phase plasminogen circulating in systemic blood also activated • Adverse effect = increased tendency for systemic bleeding • Plasmin formation occurs through out circulation = overactivation of plasminogen , neutralizing endogenous antagonist to plasmin a2 ANTIPLASMIN
  • 43. FIRST GEN : STREPTOKINASE • Streptokinase is a protein obtained from group C BETA HEMOLYTIC STREPTOCOCCI • Effective & inexpensive clot dissolving drug ~ MI • ~ Pulmonary embolism • MOA :acts as plasminogen activator = enhances production of plasmin by forming an active non covalent 1:1 complex (streptokinase : plasminogen complex ) • Plasmin catalyzes degradation of plasma proteins = clotting factor FIBRINOGEN & factor V , VII
  • 44. ADVERSE EFFECT • Foreign protein = Antigenic reactions • 2nd time use = hypersensitivity & Anaphylaxis • Over dosage = plasminogen depletion & SK resistance • Treatment over-dosage FRESH PLASMA /AMINOCAPROIC ACID
  • 45. CLINICAL INDICATIONS • Used locally as powder , infusion or irrigation of wounds which don’t responds for antibacterial therapy – burns , ulcers , chronic eczema , ear hematomas , otitis externa , osteomyelitis , chronic sinusitis • Parentrally ~ eczema , dermatitis , hematoma , trauma & pneumonia • Prophylaxis ~ reduction of post operative adhesions • Dogs: 5000 – 10,000 U (total dose) IM IV in 2 divided doses 5 days • Large animals : 5000 – 10,000 U / 45 kg BW , IM IV 2 divided dose 5 – 6 days
  • 46. SEC GEN : PLASMINOGEN ACTIVATORS • Tissue plasminogen activators • Alteplase • Reteplase • Urokinase • Streptodornase OTHER DRUGS ~ ancrod ~ fibrinolysin
  • 48. MOA • It catalyzes conversion of plasminogen to plasmin • Selective action towards the plasminogen bound to fibrin & low affinity for free plasminogen • Thus fibrinolysis to the formed clot , with out unwanted degradation of other proteins Clinical indication 1} thromboembolic strokes 2} deep vein thrombosis 3} pulmonary embolism to clear a blocked artery
  • 50. • ALTEPLASE – treatment of aortic thromboembolism Cats : 0.25 – 1 mg/kg/hour , i/v infusion for total dose of 1-10 mg/kg Dogs : 0.01 microgram/kg/min , i/v infusion for 30 min • UROKINASE – to prevent post operative lesions Dogs : 5000 – 10,000 units/kg , intra-peritoneal lavage
  • 51. END OF TOPIC - THROMBOLYTICS DISCUSSIONS
  • 56. THE ROLE OF PLATELETS
  • 57. THE ROLE OF PLATELETS
  • 58. THE ROLE OF PLATELETS
  • 59. THE ROLE OF PLATELETS
  • 60. ANTITHROMBOTIC DRUGS Antiplatelet drugs Acetylsalicylic acid (aspirin) P2Y12 antagonists Dipyridamole GPIIb/IIIa antagonists Used widely in patients at risk of thromboembolic disease Beneficial in the treatment and prevention of ACS and the prevention of thromboembolic events Secondary prevention in patients following stroke, often in combination with aspirin Administered intravenously, are effective during percutaneous coronary intervention (PCI)
  • 61. COX INHIBITORS • Aspirin ~ NSAID • MOA = irreversibly inactivates cyclooxygenase enzyme to produce pharmacological effects Reduces synthesis of thromboxane A2 = potent vasoconstrictor & inducer of platelet aggregation • Irreversibly acetylate thromboxane synthase , enzyme responsible for thromboxane synthesis • Low dose = effective in reducing platelet aggregation • High dose = blocks synthesis of prostacyclin reducing over all anti aggregatory effect
  • 62. Plaque Disruption Collagen vWF Platelet adhesion and secretion Aspirin Thrombin generation Abciximab Eptifibatide Tirofiban Platelet aggregation Platelet recruitment and activation X COX-1 TXA2 ADP X GPllb / llla activation X
  • 68. GLYCOPROTEIN II B / III A INHIBITORS • NEW CLASES of potent platelet aggregation agonists • MOA – acts by blocking glycoprotein II b / III a receptors present on surface of platelets • Glycoprotein II b / III a complex functions as receptor = vWB factor through which agonists collagen , thrombin , thromboxanes , ADP induces platelet aggregation • Drugs: 1} Abciximax – treatment of ANGIOPLASTY 2} EPTIFIBTIDE 2} tirofiban
  • 74. THROMBOXANE INHIBITORS • Acts through inhibition of thromboxane synthetase = decreases synthesis of TXA2 thus prevents platelet aggregation • Elevates endogenous cAMP in the platelets by inhibiting phosphodiesterase enzyme • Blockade of cellular reuptake of adenosine into platelets ,RBC & endothelial cells =increased extra cellular concentration of adenosine
  • 75. , 1} DIPYRIDAMOLE As synergistic with ASPIRIN With WARFARIN – to decrease the incidence of thromboembolisim in patients with PROSTHETIC HEART VALVES 2}DAZOXIBEN 3}PICOTAMIDE 4}TERUTROBAN
  • 76. MISCELLANEOUS DRUGS • CILOSTAZOL : phosphodiesterase inhibitor = intracellular concentration of cAMP = increase in PK-A = inhibition of platelet aggregation & arterial vasodilator effect Treatment – muscular pains due to cramps , numbness or fatigue • TIMOLOL ( b adrenoceptor blocker ) synergizes action of low dose aspirin • SULFINPYRAZONE uricosuric drug related to phenylbutazone Inhibits COX enzyme = blocks production of prostanoids
  • 77. REFERENCES • H RICHARD ADAMS Veterinary pharmacology and therapeutics, 8th edition. • GOODMAN & GILMAN`S The pharmacological basis of therapeutics, 11th edition. • HS SANDHU Essentials of veterinary pharmacology and toxicology, 2nd edition. • GOOGLE IMAGES • ONLINE SEARCH RELATED TOPICS

Hinweis der Redaktion

  1. September 2007
  2. September 2007
  3. September 2007
  4. September 2007
  5. September 2007
  6. September 2007
  7. September 2007
  8. September 2007
  9. September 2007
  10. September 2007
  11. September 2007
  12. September 2007
  13. September 2007
  14. September 2007
  15. September 2007
  16. September 2007
  17. September 2007
  18. September 2007
  19. September 2007
  20. September 2007
  21. September 2007
  22. September 2007
  23. September 2007